Format

Send to

Choose Destination
PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Author information

1
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Germany.
2
Department of Dermatology, Eberhard-Karls University of Tübingen, Tübingen, Germany.
3
Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany.
4
Skin Cancer Center, Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
5
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
6
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
7
Department of Dermatology, University of Mainz, Mainz, Germany.
8
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
9
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Mannheim, Germany.

Abstract

Malignant melanoma is potentially life-threatening but in most cases curable if detected early. Willingness to pay (WTP) is a preference-based construct that reflects burden of disease by assessment of the monetary value for a hypothetical cure from disease. Since WTP (directly as total amount of money) has not been assessed so far in patients with low risk melanoma, it was interesting to gain insights in this patient population and then, in a second step, compare it directly with the WTP of their treating dermato-oncologists. WTP was assessed in 125 patients with low-risk melanoma and additionally in 105 treating physicians, asking for the one-time and continuous payments they would be willing to make for a sustainable cure, both as absolute sums and as percentages of monthly income. The median WTP based on one-time payment was €10,000 for patients and €100,000 for physicians; relative numbers were 100% versus 300% of monthly income. For continuous monthly payments, WTP was €500 for patients and €1000 for physicians, relative numbers 25% and 50% of income, respectively. Even after controlling for income differences, there was a significantly higher WTP in physicians for all four questions. Compared to patients with chronic skin diseases such as vitiligo, rosacea, atopic eczema and psoriasis, patients with low-risk melanoma showed a significantly higher WTP. Our data suggest that there is a relevant burden of disease even in patients with low-risk tumors. Higher WTP of physicians underlines the prevalence of differences in disease perception.

PMID:
29795621
PMCID:
PMC5967822
DOI:
10.1371/journal.pone.0197780
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Matthias Augustin has no conflicts of interest. Christine Blome has received speaker honoraria, research grants, awards, and/or travel expenses from Celgene, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Stiefel Laboratories, The EuroQol Group, and Urgo. Andrea Forschner serves as consultant to Roche, Novartis, MSD, received travel grants from Roche, Novartis, BMS, and speaker fees from Roche, Novartis, BMS, MSD. Ralf Gutzmer received research support from: Pfizer, Johnson&Johnson, Novartis. Honoraria for lectures: Roche Pharma, Bristol-MyersSquibb, GlaxoSmithKline, Novartis, MSD, Almirall-Hermal, Amgen, Boehringer Ingelheim, AstraZeneca. Cover Letter Honoraria for advice: Roche Pharma, Bristol-MyersSquibb, GlaxoSmithKline, Novartis, MSD, Almirall-Hermal, Amgen, LEO, Pierre-Fabre, Merck-Serono, 4SC, Incyte Axel Hauschild received clinical trial support, speaker´s honoraria, or consultancy fees from Amgen, BMS, Merck Serono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche. Lucie Heinzerling serves as consultant or has received speaker fees from Roche, BMS, MSD, aAgen, Curevac, and Novartis. Her institution has received a research grant from Novartis. Elisabeth Livingstone declares advisory board and speakers honoraria from Bristol-Myers-Squibb, Boehringer-Ingelheim, Amgen, Roche, Novartis, and Merck Sharp & Dohme, as well as travel support from Amgen, Boehringer-Ingelheim, Merck Sharp & Dohme and Novartis. Carmen Loquai serves as consultant to Roche, BMS, MSD, Leo, Novartis, Amgen and Roche-Posay and received travel grants and speaker fees from Roche, BMS, MSD, Novartis, Amgen, Pierre Fabre and Roche-Posay. Dirk Schadendorf received research support from: BMS, Novartis. Honoraria: Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Amgen, Pfizer, Sanofi Honoraria for advice: Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Amgen, Pfizer, Sanofi Speakers´Bureau: Novartis, BMS, Roche. Jochen Utikal serves as consultant to Amgen, BMS, MSD, Novartis, Roche and received travel grants and speaker fees from Amgen, BMS, GSK, LeoPharma, MSD, Novartis, Roche. Tobias Wagner has no conflicts of interest. Sophia Wilden has no conflicts of interest. Katharina C Kähler serves as consultant to Roche, BMS, MSD and received travel grants and speaker fees from Roche, BMS, MSD, Amgen. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center